Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.
The Food and Drug Administration (FDA) has approved updates to the prescribing information for Belsomra® (suvorexant; Merck) to include study findings for the treatment of insomnia in patients with mild to moderate Alzheimer disease.
Individuals with Alzheimer disease (AD) initiating antipsychotics have an increased risk for head injuries and traumatic brain injury.
From 2007 to 2014, there was a decrease in the diagnosed incidence of Alzheimer disease.
Robust evidence shows households are at significant risk for large adverse changes in liquid assets.
New analysis of study results suggests highest dose of aducanumab may help slow cognitive decline.
Investigators addressed the association between long-term use of hydroxychloroquine therapy and the risk for Alzheimer disease.
Stepwise screening starts with a single question on subjective memory loss.
A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis.
Use of hearing aids is associated with lower risks for being diagnosed with Alzheimer disease, dementia, depression, anxiety, and injurious falls among elderly adults diagnosed with hearing loss.